Dianthus Therapeutics Inc
DNTHHealthcare|Biotechnology|USA
$97.54
-2.41 (-2.41%)
Tangible Book
$22.01
About
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
Stock Price
+373.3%(1Y)
Pipeline Summary
5 total trials0
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
Active: 1Recruiting: 4
Active Trials (5)
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
NCT06282159Myasthenia Gravis, Generalized
Phase 2Active
Enrollment: 65 participants
Gestational Diabetes and Perinatal Depression: an Intervention Program
NCT05800509Gestational Diabetes Mellitus
N/ARecruiting
Enrollment: 600 participants
A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy
NCT06537999Multifocal Motor Neuropathy
Phase 2Recruiting
Enrollment: 36 participants
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
NCT06858579Chronic Inflammatory Demyelinating Polyneuropathy
Phase 3Recruiting
Enrollment: 256 participants
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
NCT07647510Myasthenia Gravis, Generalized
Phase 3Recruiting
Enrollment: 195 participants
BioScore
4.9/10
Cautious
Ownership
Recent Insider Trades
Veness Adam MSELL
2026-06-1730,000 shares @ $80.8
Randhawa SimratSELL
2026-06-0126,530 shares @ $90.62
Soteropoulos PaulaSELL
2026-05-08599 shares @ $85.47
Savitz RyanSELL
2026-04-098,224 shares @ $89.84
Savitz RyanSELL
2026-03-31114,367 shares @ $83
Recent News
2026-06-29 11:30:06
Data last updated: Jul 13, 2026, 12:39 PM